Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1992 6
1993 4
1994 4
1995 1
1996 2
1997 8
1998 3
1999 2
2000 1
2001 6
2002 8
2003 14
2004 6
2005 12
2006 15
2007 10
2008 13
2009 15
2010 12
2011 19
2012 19
2013 26
2014 20
2015 12
2016 10
2017 9
2018 5
2019 2
2020 4
2021 3
2022 2
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Flather MD, et al. Eur Heart J. 2005 Feb;26(3):215-25. doi: 10.1093/eurheartj/ehi115. Epub 2005 Jan 9. Eur Heart J. 2005. PMID: 15642700 Clinical Trial.
There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcome. Death (all causes) occurred in 169 (15.8%) on nebivolol and 192 (18.1%) on placebo (HR 0.88, 95% CI 0.71-1.08; P=0.21). CONCLUSION: Nebivolo …
There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcome. Death (all …
Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.
Cannata F, Stefanini G, Carlo-Stella C, Chiarito M, Figliozzi S, Novelli L, Lisi C, Bombace S, Panico C, Cosco F, Corrado F, Masci G, Mazza R, Ricci F, Monti L, Ferrante G, Santoro A, Francone M, da Costa BR, Jüni P, Condorelli G. Cannata F, et al. J Cardiovasc Med (Hagerstown). 2023 Jul 1;24(7):469-474. doi: 10.2459/JCM.0000000000001491. J Cardiovasc Med (Hagerstown). 2023. PMID: 37285278 Clinical Trial.
This study aims to evaluate the cardioprotective effects of the beta blocker nebivolol in a prospective, placebo-controlled, superiority randomized trial in patients with breast cancer or diffuse large B cell lymphoma (DLBCL) who have a normal cardiac function and will rec …
This study aims to evaluate the cardioprotective effects of the beta blocker nebivolol in a prospective, placebo-controlled, superior …
Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure.
Van Nueten L, De Crée J. Van Nueten L, et al. Cardiovasc Drugs Ther. 1998 Sep;12(4):339-44. doi: 10.1023/a:1007760515117. Cardiovasc Drugs Ther. 1998. PMID: 9825177 Clinical Trial.
Similar effects on both exercise-induced tachycardia and increases in systolic blood pressure were seen with nebivolol 5.0 mg and with d-nebivolol 2.5 mg; l-nebivolol 2.5 mg was no different from placebo. ...Nebivolol had a clearly superior trough-to-p …
Similar effects on both exercise-induced tachycardia and increases in systolic blood pressure were seen with nebivolol 5.0 mg and wit …
Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients.
Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Himmelmann A, et al. Eur J Clin Pharmacol. 1996;51(3-4):259-64. doi: 10.1007/s002280050194. Eur J Clin Pharmacol. 1996. PMID: 9010695 Clinical Trial.
OBJECTIVE: Nebivolol is a selective beta 1-adrenergic receptor blocker possessing an ancillary vasodilating effect. ...Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significa …
OBJECTIVE: Nebivolol is a selective beta 1-adrenergic receptor blocker possessing an ancillary vasodilating effect. ...Calculated per …
The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross-over study.
Bikos A, Loutradis C, Angeloudi E, Karpetas A, Raptis V, Kalaitzidis R, Panagoutsos S, Pasadakis P, Balaskas I, Liakopoulos V, Papagianni A, Sarafidis PA. Bikos A, et al. J Hypertens. 2019 Feb;37(2):432-442. doi: 10.1097/HJH.0000000000001891. J Hypertens. 2019. PMID: 30063644 Clinical Trial.
No significant differences were observed in comparisons between the two drugs, with the exception of heart rate, being lower with nebivolol. CONCLUSION: Both nebivolol and irbesartan reduced postdialysis and 24-h BP in patients with intradialytic hypertension. Weekl …
No significant differences were observed in comparisons between the two drugs, with the exception of heart rate, being lower with nebivol …
The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.
Studinger P, Tabák ÁG, Chen CH, Salvi P, Othmane TE, Torzsa P, Kapocsi J, Fekete BC, Tislér A. Studinger P, et al. J Clin Hypertens (Greenwich). 2013 Dec;15(12):910-7. doi: 10.1111/jch.12210. Epub 2013 Oct 4. J Clin Hypertens (Greenwich). 2013. PMID: 24119182 Free PMC article. Clinical Trial.
AIx remained unchanged, while AIx@75 decreased significantly by 5.4%2.5% in the nebivolol group. According to general linear models, individual change in heart rate was a strong predictor of change in AIx in the carvedilol group (r(2) =0.23, P=.03) although no similar asso …
AIx remained unchanged, while AIx@75 decreased significantly by 5.4%2.5% in the nebivolol group. According to general linear models, …
Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial.
Lacourcière Y, Lefebvre J, Poirier L, Archambault F, Arnott W. Lacourcière Y, et al. Am J Hypertens. 1994 Feb;7(2):137-45. doi: 10.1093/ajh/7.2.137. Am J Hypertens. 1994. PMID: 8179848 Clinical Trial.
After a 4-week placebo period, 240 white patients with a mean daytime ambulatory blood pressure of > or = 90 mm Hg were randomized to receive either placebo, nebivolol (1, 5, or 10 mg), hydrochlorothiazide (12.5 or 25 mg), or one of the six possible combinations of n …
After a 4-week placebo period, 240 white patients with a mean daytime ambulatory blood pressure of > or = 90 mm Hg were randomized to rec …
Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial.
Uhlir O, Dvorak I, Gregor P, Malek I, Spinarova L, Vojacek J, Van Nueten L. Uhlir O, et al. J Card Fail. 1997 Dec;3(4):271-6. doi: 10.1016/s1071-9164(97)90026-9. J Card Fail. 1997. PMID: 9547441 Clinical Trial.
One patient on nebivolol 2.5 mg developed hypotension and pulmonary edema, and one patient on nebivolol 5 mg, bradycardia. ...CONCLUSIONS: In view of increasing interest in beta-blockade in heart failure, nebivolol merits further study in this context. The ca …
One patient on nebivolol 2.5 mg developed hypotension and pulmonary edema, and one patient on nebivolol 5 mg, bradycardia. ... …
The effect of nebivolol and ramipril on selected biochemical parameters, arterial stiffness, and circadian profile of blood pressure in young men with primary hypertension: A 12-week prospective randomized, open-label study trial.
Walczak-Gałęzewska M, Szulińska M, Miller-Kasprzak E, Pupek-Musialik D, Bogdański P. Walczak-Gałęzewska M, et al. Medicine (Baltimore). 2018 Jul;97(30):e11717. doi: 10.1097/MD.0000000000011717. Medicine (Baltimore). 2018. PMID: 30045336 Free PMC article. Clinical Trial.
RESULTS: After the treatment period, we observed significant decreases in both ABPM systolic blood pressure (SBP) in group of nebivolol (P = .0007) and ramipril (P = .0001) and in ABPM diastolic blood pressure (DBP) in group of nebivolol (P = .0018) and ramipril (P …
RESULTS: After the treatment period, we observed significant decreases in both ABPM systolic blood pressure (SBP) in group of nebivolol …
Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
Park K, Park TH. Park K, et al. Trials. 2016 Nov 3;17(1):530. doi: 10.1186/s13063-016-1656-y. Trials. 2016. PMID: 27809882 Free PMC article. Clinical Trial.
No study has specifically compared the relative effectiveness of carvedilol and nebivolol in treating HF in older patients with preserved EF. METHOD/DESIGN: This trial is a prospective, randomized, open-label, single-centre, active controlled study designed to investigate …
No study has specifically compared the relative effectiveness of carvedilol and nebivolol in treating HF in older patients with prese …
246 results